ABEO Abeona Therapeutics Inc.

6.47
+0.09  (+1%)
Previous Close 6.38
Open 6.42
Price To Book 2.07
Market Cap 310200824
Shares 47,944,486
Volume 195,921
Short Ratio
Av. Daily Volume 542,101

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 ongoing as of December 6, 2018.
ABO-101
Sanfilippo syndrome type B (MPS IIIB)
Pivotal trial to be initiated mid-2019.
EB-101
Recessive dystrophic epidermolysis bullosa (RDEB)
Phase 1/2 safety and tolerability data to be presented at WORLDSymposium February 6, 2019.
ABO-102
Sanfilippo syndrome type A (MPS IIIA)

Latest News

  1. What Investors Should Know About Abeona Therapeutics Inc.’s (NASDAQ:ABEO) Financial Strength
  2. Abeona Therapeutics Announces Participation in 8th Annual SVB Leerink Global Healthcare Conference
  3. New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
  4. Abeona Therapeutics Appoints João Siffert, M.D. Chief Executive Officer
  5. The Unknown Biotech Play that Could Deliver 400% Returns, or Much More
  6. Abeona Therapeutics to Present New Supportive Data for Novel Gene Therapies at WORLDSymposium™
  7. Abeona Therapeutics Strengthens Financial Leadership with New Executive Appointments
  8. How Should Investors Feel About Abeona Therapeutics Inc.’s (NASDAQ:ABEO) CEO Pay?
  9. Is Abeona Therapeutics Inc (ABEO) A Good Stock To Buy?
  10. Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher
  11. Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump
  12. Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day
  13. Moving Average Crossover Alert: Abeona Therapeutics
  14. Abeona Therapeutics to Host R&D Day on December 6, 2018
  15. Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  16. Abeona Therapeutics Announces CEO Transition
  17. Edited Transcript of ABEO earnings conference call or presentation 12-Nov-18 3:00pm GMT
  18. Abeona Therapeutics (ABEO) Reports Q3 Loss, Tops Revenue Estimates
  19. Abeona Therapeutics: 3Q Earnings Snapshot